CellChorus

CellChorus announced that it has expanded its commercial and R&D facilities in Houston. The expansion will support CellChorus working with additional customers and partners in the cell and gene therapy, antibody and vaccine markets.

HOUSTON, Texas — February 16, 2022 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, will present at the 2022 Texas Life Science Forum.

HOUSTON, Texas — March 1, 2022 — CellChorus Inc., the leader in applying artificial intelligence to visually evaluate how thousands of individual cells perform over time, announced today that it will present at the 2022 MIT Health Science Technologies Conference: The Future of Cell & Gene Therapies.

Scientists from CellChorus Inc. published a report finding that cytotoxic T lymphocytes (CTLs) targeting a conserved SARS-CoV-2 spike epitope are efficient serial killers.

The company seeks candidates in Houston and the San Francisco Bay Area with experience in single-cell analysis, immunology, adoptive cell therapy, immunotherapy, microscopy, flow cytometry, image processing, bioinformatics, ImageJ, and cell culture.

CellChorus is a single-cell, visual AI company that applies Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) to understand how thousands of cells behave

CellChorus offers a single-cell visual AI platform to support the efficacy, safety, or manufacturing efficiency of immunology programs.

CellChorus conducts dynamic single-cell analysis at scale. Time-lapse Imaging Microscopy in Nanowell Grids (TIMING) uses visual AI to evaluate how cells behave in a variety of environmental conditions.